AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (December 23, 2003). doi:10.1152/ajpheart.00544.2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/5/H1767    most recent
00544.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gonon, A. T.
Right arrow Articles by Pernow, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gonon, A. T.
Right arrow Articles by Pernow, J.
Submitted on June 12, 2003
Accepted on December 17, 2003

Nitric oxide mediates the protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion

Adrian T. Gonon1*, Deniz Erbas1, Anders Broijersen2, Guro Valen3, and John Pernow1

1 Department of Cardiology, Karolinska Hospital, Stockholm, Sweden
2 Center for metabolism and endocrinology, Huddinge University Hospital, Huddinge, Sweden
3 Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden

* To whom correspondence should be addressed. E-mail: adrian.gonon{at}medks.ki.se.

Endothelin (ET) receptor antagonism protects from ischemia-reperfusion injury. We hypothesized that the cardioprotective effect is related to nitric oxide (NO) bioavailability. Buffer-perfused rat and mouse hearts were subjected to ischemia and reperfusion. At the onset of ischemia the rat hearts received vehicle, the dual ETA/ETB receptor antagonist bosentan (10µM), the NO synthase inhibitor L-NMMA (100µM), the combination of bosentan and L-NMMA or the combination of bosentan, L-NMMA and the NO substrate L-arginine (1mM). Hearts from wild type and endothelial NO synthase (eNOS) deficient mice received either vehicle or bosentan. Myocardial performance, endothelial function, NO outflow and eNOS expression were monitored. Bosentan significantly improved myocardial function during reperfusion in rats and in wild type mice, but not in eNOS deficient mice. The functional protection afforded by bosentan was inhibited by L-NMMA, whereas it was restored by L-arginine. Myocardial expression of eNOS (immunoblotting) increased significantly in bosentantreated rat hearts in comparison with vehicle hearts. Recovery of NO outflow during reperfusion was enhanced in the bosentan treated rat heart. The endothelium-dependent vasodilator adenosine diphosphate increased coronary flow by 18±9% at the end of reperfusion in the bosentan group, whereas it reduced coronary flow by 7±5% in the vehicle group (P<0.001). The response to the endothelium-independent dilator sodium nitroprusside was not different between the two groups. In conclusion, the dual ETA/ETB receptor antagonist bosentan preserved endothelial and cardiac contractile function during ischemia and reperfusion via a mechanism dependent on endothelial NO production.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1976 by the American Physiological Society.